CUT COVID-19: The Corona Study of Middle Norway
Sponsor
St. Olavs Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05638178
Collaborator
The Research Council of Norway (Other), Alesund Hospital (Other), Namsos Hospital (Other), Molde Hospital (Other), Helse Nord-Trøndelag HF (Other)
223
5
27.4
44.6
1.6
Study Details
Study Description
Brief Summary
CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during hospitalization, as well as data from a followup consultation 3 months after discharge.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
223 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Middle Norway Corona Study - Individual and Genetic Risk Factors for COVID-19 Infection.
Actual Study Start Date
:
May 1, 2020
Actual Primary Completion Date
:
Dec 31, 2021
Actual Study Completion Date
:
Aug 12, 2022
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Adult 18+ |
Other: No intervention
No intervention, cohort study.
|
| Pediatric Under 18 |
Other: No intervention
No intervention, cohort study.
|
Outcome Measures
Primary Outcome Measures
- Predictors of COVID-19 severity [1 year after inclusion.]
Primary aim is to assess predictors of severe COVID disease in children and adults
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Positive SARS CoV-2 infection
Exclusion Criteria:
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | St. Olavs Hospital | Trondheim | MN | Norway | 7006 |
| 2 | Molde Hospital | Molde | MR | Norway | 6405 |
| 3 | Ålesund Hospital | Ålesund | MR | Norway | 6017 |
| 4 | Levanger Hospital | Levanger | NT | Norway | 7600 |
| 5 | Namsos Hospital | Namsos | NT | Norway | 7800 |
Sponsors and Collaborators
- St. Olavs Hospital
- The Research Council of Norway
- Alesund Hospital
- Namsos Hospital
- Molde Hospital
- Helse Nord-Trøndelag HF
Investigators
- Principal Investigator: Kari Risnes, MD/PhD, St. Olavs Hospital
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021 Dec;600(7889):472-477. doi: 10.1038/s41586-021-03767-x. Epub 2021 Jul 8.
- Degenhardt F, Ellinghaus D, Juzenas S, Lerga-Jaso J, Wendorff M, Maya-Miles D, Uellendahl-Werth F, ElAbd H, Ruhlemann MC, Arora J, Ozer O, Lenning OB, Myhre R, Vadla MS, Wacker EM, Wienbrandt L, Blandino Ortiz A, de Salazar A, Garrido Chercoles A, Palom A, Ruiz A, Garcia-Fernandez AE, Blanco-Grau A, Mantovani A, Zanella A, Holten AR, Mayer A, Bandera A, Cherubini A, Protti A, Aghemo A, Gerussi A, Ramirez A, Braun A, Nebel A, Barreira A, Lleo A, Teles A, Kildal AB, Biondi A, Caballero-Garralda A, Ganna A, Gori A, Gluck A, Lind A, Tanck A, Hinney A, Carreras Nolla A, Fracanzani AL, Peschuck A, Cavallero A, Dyrhol-Riise AM, Ruello A, Julia A, Muscatello A, Pesenti A, Voza A, Rando-Segura A, Solier A, Schmidt A, Cortes B, Mateos B, Nafria-Jimenez B, Schaefer B, Jensen B, Bellinghausen C, Maj C, Ferrando C, de la Horra C, Quereda C, Skurk C, Thibeault C, Scollo C, Herr C, Spinner CD, Gassner C, Lange C, Hu C, Paccapelo C, Lehmann C, Angelini C, Cappadona C, Azuure C; COVICAT study group, Aachen Study (COVAS); Bianco C, Cea C, Sancho C, Hoff DAL, Galimberti D, Prati D, Haschka D, Jimenez D, Pestana D, Toapanta D, Muniz-Diaz E, Azzolini E, Sandoval E, Binatti E, Scarpini E, Helbig ET, Casalone E, Urrechaga E, Paraboschi EM, Pontali E, Reverter E, Calderon EJ, Navas E, Solligard E, Contro E, Arana-Arri E, Aziz F, Garcia F, Garcia Sanchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandi F, Kurth F, Blasi F, Malvestiti F, Medrano FJ, Mesonero F, Rodriguez-Frias F, Hanses F, Muller F, Hemmrich-Stanisak G, Bellani G, Grasselli G, Pezzoli G, Costantino G, Albano G, Cardamone G, Bellelli G, Citerio G, Foti G, Lamorte G, Matullo G, Baselli G, Kurihara H, Neb H, My I, Kurth I, Hernandez I, Pink I, de Rojas I, Galvan-Femenia I, Holter JC, Afset JE, Heyckendorf J, Kassens J, Damas JK, Rybniker J, Altmuller J, Ampuero J, Martin J, Erdmann J, Banales JM, Badia JR, Dopazo J, Schneider J, Bergan J, Barretina J, Walter J, Hernandez Quero J, Goikoetxea J, Delgado J, Guerrero JM, Fazaal J, Kraft J, Schroder J, Risnes K, Banasik K, Muller KE, Gaede KI, Garcia-Etxebarria K, Tonby K, Heggelund L, Izquierdo-Sanchez L, Bettini LR, Sumoy L, Sander LE, Lippert LJ, Terranova L, Nkambule L, Knopp L, Gustad LT, Garbarino L, Santoro L, Tellez L, Roade L, Ostadreza M, Intxausti M, Kogevinas M, Riveiro-Barciela M, Berger MM, Schaefer M, Niemi MEK, Gutierrez-Stampa MA, Carrabba M, Figuera Basso ME, Valsecchi MG, Hernandez-Tejero M, Vehreschild MJGT, Manunta M, Acosta-Herrera M, D'Angio M, Baldini M, Cazzaniga M, Grimsrud MM, Cornberg M, Nothen MM, Marquie M, Castoldi M, Cordioli M, Cecconi M, D'Amato M, Augustin M, Tomasi M, Boada M, Dreher M, Seilmaier MJ, Joannidis M, Wittig M, Mazzocco M, Ciccarelli M, Rodriguez-Gandia M, Bocciolone M, Miozzo M, Imaz Ayo N, Blay N, Chueca N, Montano N, Braun N, Ludwig N, Marx N, Martinez N; Norwegian SARS-CoV-2 Study group; Cornely OA, Witzke O, Palmieri O; Pa Study Group; Faverio P, Preatoni P, Bonfanti P, Omodei P, Tentorio P, Castro P, Rodrigues PM, Espana PP, Hoffmann P, Rosenstiel P, Schommers P, Suwalski P, de Pablo R, Ferrer R, Bals R, Gualtierotti R, Gallego-Duran R, Nieto R, Carpani R, Morilla R, Badalamenti S, Haider S, Ciesek S, May S, Bombace S, Marsal S, Pigazzini S, Klein S, Pelusi S, Wilfling S, Bosari S, Volland S, Brunak S, Raychaudhuri S, Schreiber S, Heilmann-Heimbach S, Aliberti S, Ripke S, Dudman S, Wesse T, Zheng T; STORM Study group, The Humanitas Task Force, The Humanitas Gavazzeni Task Force; Bahmer T, Eggermann T, Illig T, Brenner T, Pumarola T, Feldt T, Folseraas T, Gonzalez Cejudo T, Landmesser U, Protzer U, Hehr U, Rimoldi V, Monzani V, Skogen V, Keitel V, Kopfnagel V, Friaza V, Andrade V, Moreno V, Albrecht W, Peter W, Poller W, Farre X, Yi X, Wang X, Khodamoradi Y, Karadeniz Z, Latiano A, Goerg S, Bacher P, Koehler P, Tran F, Zoller H, Schulte EC, Heidecker B, Ludwig KU, Fernandez J, Romero-Gomez M, Albillos A, Invernizzi P, Buti M, Duga S, Bujanda L, Hov JR, Lenz TL, Asselta R, de Cid R, Valenti L, Karlsen TH, Caceres M, Franke A. Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Hum Mol Genet. 2022 Nov 28;31(23):3945-3966. doi: 10.1093/hmg/ddac158.
- Ponsford MJ, Gkatzionis A, Walker VM, Grant AJ, Wootton RE, Moore LSP, Fatumo S, Mason AM, Zuber V, Willer C, Rasheed H, Brumpton B, Hveem K, Kristian Damas J, Davies N, Asvold BO, Solligard E, Jones S, Burgess S, Rogne T, Gill D. Cardiometabolic Traits, Sepsis, and Severe COVID-19: A Mendelian Randomization Investigation. Circulation. 2020 Nov 3;142(18):1791-1793. doi: 10.1161/CIRCULATIONAHA.120.050753. Epub 2020 Sep 23. No abstract available.
Responsible Party:
St. Olavs Hospital
ClinicalTrials.gov Identifier:
NCT05638178
Other Study ID Numbers:
- 121891
First Posted:
Dec 6, 2022
Last Update Posted:
Dec 6, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: